Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Romeijn

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The British Journal of Dermatology|November 8, 2023
Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial)Aviël Ragamin, Renske Schappin, Marlies de Graaf, et al.
Trials|December 13, 2021
The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trialAviël Ragamin, Karin B Fieten, Ron A Tupker, et al.
Allergy|October 9, 2019
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registryLieneke F M Ariëns, Jorien van der Schaft, Daphne S Bakker, et al.
JAMA Dermatology|August 10, 2022
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Nicolaas P A Zuithoff, et al.
Journal of the American Academy of Dermatology|April 23, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJunfen Zhang, Celeste M Boesjes, Laura Loman, et al.
JAMA Dermatology|August 7, 2024
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic DermatitisCeleste M Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
The British Journal of Dermatology|April 20, 2018
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)J R Chalmers, K S Thomas, C Apfelbacher, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The British Journal of Dermatology|November 8, 2023
Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial)Aviël Ragamin, Renske Schappin, Marlies de Graaf, et al.
Trials|December 13, 2021
The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trialAviël Ragamin, Karin B Fieten, Ron A Tupker, et al.
Allergy|October 9, 2019
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registryLieneke F M Ariëns, Jorien van der Schaft, Daphne S Bakker, et al.
JAMA Dermatology|August 10, 2022
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Nicolaas P A Zuithoff, et al.
Journal of the American Academy of Dermatology|April 23, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJunfen Zhang, Celeste M Boesjes, Laura Loman, et al.
JAMA Dermatology|August 7, 2024
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic DermatitisCeleste M Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
The British Journal of Dermatology|April 20, 2018
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)J R Chalmers, K S Thomas, C Apfelbacher, et al.
Pageof 3